GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised

Glaukos Corporation (GKOS) reported a narrower-than-expected Q2 2025 adjusted loss of 24 cents per share and revenue of $124.1 million, a 29.7% year-over-year increase, both surpassing consensus estimates, primarily driven by strong iDose TR uptake and Photrexa sales. The company also raised its 2025 revenue guidance to $480-$486 million and cited significant pipeline progress, including Epioxa's targeted FDA approval by October 2025. Despite these positive financial results and strategic advancements, GKOS shares declined 2.2% in after-market trading, reflecting persistent investor concerns over headwinds such as restrictive Local Coverage Determinations and procedural bundling impacting non-iDose stent volumes.

Analysis

Glaukos Corporation (GKOS) delivered a strong second-quarter 2025 performance, exceeding consensus estimates on both revenue and earnings. The company reported revenue of $124.1 million, a 29.7% year-over-year increase, driven by the robust commercial uptake of its new iDose TR therapy and solid sales from its Corneal Health segment. This top-line strength translated into improved profitability, with the adjusted loss narrowing to 24 cents per share from 52 cents in the prior-year quarter, and the adjusted gross margin expanding to 83%. In a sign of confidence, management raised its full-year 2025 revenue guidance to a range of $480-$486 million. Despite these positive operational metrics and a strengthening pipeline highlighted by the targeted October 2025 FDA approval for Epioxa, the stock reacted negatively, falling 2.2% in after-market trading. This investor response underscores the significant headwinds the company faces, specifically restrictive Local Coverage Determinations that are causing a mid-single-digit decline in non-iDose stent volumes and persistent pressure from procedural bundling. The stock's 37.2% year-to-date decline suggests the market is heavily weighing these regulatory and reimbursement risks against the company's demonstrated growth and pipeline potential.

Key Decisions for Investors

• Investors should weigh the company's strong execution on new product launches like iDose TR and improved profitability against the persistent regulatory headwinds impacting its legacy stent business.
• The negative stock reaction to a positive earnings report indicates that the market is focused on risk, so it is crucial to monitor for any changes in Local Coverage Determinations or updates on the pipeline, particularly the targeted FDA approval of Epioxa in October 2025.
• Given the stock's significant underperformance year-to-date, consider whether current valuation adequately reflects the execution risk or if the market is overly pessimistic about the company's ability to navigate the complex reimbursement environment.